Lynn Sage Comprehensive Breast Center plays role in newly approved breast cancer drug, ABRAXANE
Chicago, IL January 7, 2005 Researchers at Lynn Sage Comprehensive Breast Center played a significant role in the U.S. Food and Drug Administration (FDA) approval of ABRAXANETM (paclitaxel protein bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.... ..."This approval means that women with metastatic breast cancer no longer need to endure the to...FDA approves ABRAXANE(TM) for metastatic breast cancer
SCHAUMBURG, IL January 7, 2005 American Pharmaceutical Partners, Inc. (NASDAQ:APPX) and American Bioscience, Inc. (ABI) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRAXANETM for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer. ABRAXANE is indicated for the treatment of breast ca...US Oncology, Inc. plays role in newly approved ABRAXANE for metastatic breast cancer
Houston, Texas, January 10, 2005 Thirty-eight US Oncology, Inc. (NASDAQ:USON) affiliated medical centers nationwide continue to play a significant role in the clinical research of ABRAXANE that was approved today by the U.S. Food and Drug Administration (FDA). ABRAXANETM (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of alb...